TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04343963
Drug: Pyridostigmine Bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 60mg tablet P.O. once per day for 14 days
Study: NCT00138580
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00851747
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Study: NCT03431428
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
Study: NCT02321800
Drug: Cefiderocol
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Study: NCT02321800
Drug: Imipenem/cilastatin
Normalized name: imipenem/cilastatin/relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Study: NCT00120835
Drug: valopicitabine
Normalized name: Valtorcitabine
DrugBank: Valopicitabine (DB13920)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00120835
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01854710
Drug: ADASUVE 10 mg 2 doses 2 hours apart
Normalized name: Adasuve
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled loxapine 10 mg 2 doses 2 hours apart
Study: NCT01854710
Drug: Oral moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral moxifloxacin 400 mg single dose
Study: NCT03053284
Drug: Pasireotide 0.6Mg Solution for Injection
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide 0.6Mg Solution for Injection will be given once per study visit
Study: NCT03053284
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline Solution injection will be given once per study visit
Study: NCT00982878
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg twice daily
Study: NCT03951571
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
Study: NCT02215512
Drug: RRx-001 + WBRT
Normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
Study: NCT02407353
Drug: PF-06648671
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
Study: NCT00967135
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg oral dose of pregabalin twice daily for 5 consecutive days.
Study: NCT02120677
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
Study: NCT00064831
Drug: Black Cohosh Extract (BCE)
Normalized name: BLACK COHOSH EXTRACT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03924401
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
Study: NCT00299988
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00834444
Drug: Famciclovir 500 mg Tablets
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x 500 mg, single-dose fasting
Study: NCT01262001
Drug: FG-3019
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
Study: NCT01262001
Drug: FG-3019
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
Study: NCT03679091
Drug: low-dose ticagrelor
Normalized name: ethinyl estradiol
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
Study: NCT03679091
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
Study: NCT02121067
Drug: Levonorgestrel Intrauterine System (LNG-IUS)
Normalized name: levonorgestrel Intrauterine System
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
Study: NCT04418167
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib capsules for oral administration
Study: NCT02890069
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02890069
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02817100
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
Study: NCT03167411
Drug: Bexagliflozin
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin tablets, 20 mg
Study: NCT03167411
Drug: Exenatide Injection
Normalized name: exenatide Injection
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
Study: NCT01055535
Drug: Microplasmin
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 125 µg intravitreal injection
Study: NCT03885778
Drug: Besifovir dipivoxil
Normalized name: Besifovir dipivoxil
DrugBank: Besifovir dipivoxil (DB05020)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg Besifovir dipivoxil, single dose, oral
Study: NCT01385215
Drug: Fluzone
Normalized name: Fluzone
DrugBank: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (DB10791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/15 micrograms
Study: NCT01385215
Drug: Fluzone
Normalized name: Fluzone
DrugBank: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (DB10791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/60 micrograms
Study: NCT00456560
Drug: AV650
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00456560
Drug: Fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00456560
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02273492
Drug: Asasantin ER
Normalized name: Afsantin
DrugBank: Wormwood (DB14291)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02936830
Drug: 5% Sodium Fluoride Varnish
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% sodium fluoride varnish applied on the dentin by the dentist
Study: NCT02936830
Drug: Glycerol
Normalized name: Glycerol
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol with water in a 1: 1 ratio
Study: NCT03962010
Drug: GX-G6
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: long acting anti-diabetic drug
Study: NCT03962010
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control
Study: NCT00669162
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/m2 IV weekly for 7 weeks
Study: NCT04665830
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treated patients with evolocumab for high cholesterol
Study: NCT03208231
Drug: Combination Antiretroviral Therapy (cART)
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All infants received non-study provided cART selected by their primary care provider and supplied through non-study sources (i.e., cART not provided through the study).
Study: NCT02331563
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ultrasound guided transvers abdominis plane block
Study: NCT02331563
Drug: 0.25 % bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided transvers abdominis plane block
Study: NCT04983160
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol
Study: NCT01634139
Drug: Tiotropium low dose QD
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 actuations once daily in the evening
Study: NCT01634139
Drug: Tiotropium high dose QD
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 actuations once daily in the evening
Study: NCT00044434
Drug: bupropion (Wellbutrin)
Normalized name: bupropion Oral Tablet [Wellbutrin]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00918684
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg tab daily
Study: NCT00402103
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
Study: NCT03871478
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Arm Description
Study: NCT03871478
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Arm Description
Study: NCT03871478
Drug: Lidocaine and Bupivacaine
Normalized name: bupivacaine / lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Arm Description
Study: NCT00862095
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target does 80 mg per day for 3 months
Study: NCT00862095
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target does of 50 mg per day for 3 months
Study: NCT00862095
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target dose 100 mg a day for 3 months
Study: NCT00402103
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
Study: NCT00402103
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
Study: NCT00484679
Drug: Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
Study: NCT00740831
Drug: leuprorelin
Normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution for injection
Study: NCT01830972
Drug: SA-ER 500 mg
Normalized name: amphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT00191490
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00191490
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00191490
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02319993
Drug: TIAN WANG BU XIN DAN
Normalized name: Tian Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
Study: NCT02319993
Drug: Suan Tzao Ren Tang
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
Study: NCT03214588
Drug: TAK-831
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 tablets
Study: NCT05549570
Drug: Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
Study: NCT01798628
Drug: Treatment A: abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
Study: NCT01798628
Drug: Treatment B: abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
Study: NCT01798628
Drug: Treatment C: abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Study: NCT03393572
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%
Study: NCT03393572
Drug: Magnesium sulphate.
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.
Study: NCT03393572
Drug: nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive intraperitoneal 5 mg nalbuphine
Study: NCT01895764
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
Study: NCT01111448
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
Study: NCT00152451
Drug: Seletracetam (ucb 44212)
Normalized name: Levetiracetam
DrugBank: Seletracetam (DB05885)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Pharmaceutical form: oral capsules~* Concentration: 10 and 50 mg~* Route of administration: oral administration
Study: NCT02624908
Drug: canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
Study: NCT02408315
Drug: misoprostol/placebo
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
Study: NCT03475251
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
Study: NCT03703154
Drug: Envarsus
Normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
Study: NCT03703154
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient's physician will prescribe drug according to standard practice.
Study: NCT01731457
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: adding appropriate dose of etanercept to the perfusion fluid
Study: NCT05291195
Drug: Essential Oil
Normalized name: Essential oil
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)
Study: NCT05291195
Drug: Sodium hypochlorite group
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
Study: NCT00023166
Drug: PEG-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01103843
Drug: Loading Dose Arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
Study: NCT01815515
Drug: 18F-DCFBC
Normalized name: (18F)-Fluoride
DrugBank: DCFBC F-18 (DB14772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
Study: NCT00367133
Drug: 1mg triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
Study: NCT00171730
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01366209
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
Study: NCT00367133
Drug: 4mg triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
Study: NCT03694197
Drug: Praluent
Normalized name: Praluent
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) administration